Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Response rate as an endpoint in clinical trials.

× No keyword cloud information.

10 in total

Review 1. Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?

Authors: Lothar R Pilz; Christian Manegold; Gerald Schmid-Bindert
Journal: Transl Lung Cancer Res Date: 2012-03

2. Trends in endpoint selection in clinical trials of advanced breast cancer.

Authors: Seung Yeon Song; Heenam Seo; Gyungjin Kim; Ah Rong Kim; Eun Young Kim
Journal: J Cancer Res Clin Oncol Date: 2016-09-01 Impact factor: 4.553

3. Overexpression of stathmin is resistant to paclitaxel treatment in patients with non-small cell lung cancer.

Authors: Ruifang Sun; Zhigang Liu; Lumin Wang; Weidong Lv; Jia Liu; Caixia Ding; Yong Yuan; Guangyan Lei; Changfu Xu
Journal: Tumour Biol Date: 2015-04-18

4. Role of pemetrexed in advanced non-small-cell lung cancer: meta-analysis of randomized controlled trials, with histology subgroup analysis.

Authors: K Al-Saleh; C Quinton; P M Ellis
Journal: Curr Oncol Date: 2012-02 Impact factor: 3.677

Review 5. Opportunities and pitfalls of cancer imaging in clinical trials.

Authors: Bruno Morgan
Journal: Nat Rev Clin Oncol Date: 2011-04-26 Impact factor: 66.675

6. Short-term and long-term prognostic value of histological response and intensified chemotherapy in osteosarcoma: a retrospective reanalysis of the BO06 trial.

Authors: Eni Musta; Nan van Geloven; Jakob Anninga; Hans Gelderblom; Marta Fiocco
Journal: BMJ Open Date: 2022-05-10 Impact factor: 3.006

7. Reporting trends of outcome measures in phase II and phase III trials conducted in advanced-stage non-small-cell lung cancer.

Authors: Saurav Ghimire; Eunjung Kyung; Eunyoung Kim
Journal: Lung Date: 2013-05-30 Impact factor: 2.584

Review 8. Challenges in translating endpoints from trials to observational cohort studies in oncology.

Authors: Anne Gulbech Ording; Deirdre Cronin-Fenton; Vera Ehrenstein; Timothy L Lash; John Acquavella; Mikael Rørth; Henrik Toft Sørensen
Journal: Clin Epidemiol Date: 2016-06-11 Impact factor: 4.790

9. Toward developing a metastatic breast cancer treatment strategy that incorporates history of response to previous treatments.

Authors: Aleksandra K Olow; Laura van 't Veer; Denise M Wolf
Journal: BMC Cancer Date: 2021-03-01 Impact factor: 4.430

10. Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways.

Authors: A-M Cleton-Jansen; J K Anninga; I H Briaire-de Bruijn; S Romeo; J Oosting; R M Egeler; H Gelderblom; A H M Taminiau; P C W Hogendoorn
Journal: Br J Cancer Date: 2009-11-03 Impact factor: 7.640

10 in total